Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Ophthalmology
Published in: International Ophthalmology 6/2018

01-12-2018 | Original Paper

Efficacy of locally produced Latanoprost in the control of intraocular pressure in patients with primary open-angle glaucoma

Authors: Pir Salim Mahar, Nadeem H. Butt, Syed Imtiaz Ali

Published in: International Ophthalmology | Issue 6/2018

Login to get access

Abstract

Purpose

To determine the efficacy of locally produced Latanoprost in reducing the intraocular pressure (IOP) in patients with Primary open-angle glaucoma (POAG).

Design

Open-label, non-comparative, observational case study with non-probability purposive sampling.

Methods

A total of 48 patients (94 eyes) of either gender were recruited from glaucoma clinic with the diagnosis of POAG, having IOP of more than 21 mmHg. Patients were commenced on locally produced Latanoprost (Vislat 0.005%). IOP was subsequently measured at 4 weeks and 12 weeks, respectively. The primary end point was reduction in IOP at 12 weeks after the initiation of treatment.

Results

A total of 48 patients (94 eyes) were recruited from glaucoma clinic. The average IOP of our patients at baseline was 28.6 ± 8.1 mmHg, decreasing to 21.3 ± 10.6 mmHg at 4 weeks, indicating a drop of 19.1% (P < 0.001). IOP further decreased to 20.3 ± 8.7 mmHg after 3 months of treatment indicating a decrease of 23.3% (P < 0.001). A decrease in IOP occurred in 51 eyes (71.8%) at 4 weeks after treatment, improving to 54 eyes (76%) at 3-month follow-up. Twenty eyes (28.1%) did not show any change in IOP at 4 weeks. However, after 3-month follow-up only 17 eyes (23.9%) did not reveal any change in IOP.

Conclusion

Our results showed a decrease in IOP of 19.1% after 4 weeks, increasing to 23.3% at 12 weeks in cohort of 37 patients (72 eyes) treated with locally produced Latanoprost (Vislat 0.005%).
Literature
1.
Ocklind A (1998) Effect of Latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res 67:179–191CrossRef
2.
Kim JW, Lindsey JD, Wang N et al (2001) Increased human sclera permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci 42:1514–1521PubMed
3.
Larsson LI (2001) Intraocular pressure over 24 hours after single-dose administration of Latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study. Acta Ophthalmol Scand 79:567–571CrossRef
4.
Camras CB (1996) Comparison of Latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 103:138–147CrossRef
5.
Aml A, Stjernschantz J (1995) Effects on intraocular pressure and side effects of 0.005% Latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 102:1743–1752CrossRef
6.
Watson P, Stjernschantz J (1996) A six-month randomized, double-masked study comparing Latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 103:126–137CrossRef
7.
Hedman K, Watson P, Alm A (2002) The effect of Latanoprost on Intraocular pressure during 2 years of treatment. Survey Ophthalmol 47:65–75CrossRef
8.
Allauire C, Dietrich A, Allmeir H, Grundmane I, Mazur-Piotrowska G, Kahle G (2012) Latanoprost 0.005%, test formulation is as effective as Xalatan in patients with ocular hypertension and primary open angle glaucoma. Eur J Ophthalmol 22(1):19–27CrossRef
9.
Golan S, Rosenfeld E, Shemesh G, Kurtz S (2015) Original and generic Latanoprost for the treatment of glaucoma and ocular hypertension are really the same? Clin Exp Pharmacol Physiol 42(2):220–224CrossRef
10.
Digiuni M, Manni G, Vetrugno M, Uva M, Milano G, Orzalesi N et al (2013) An evaluation of therapeutic non-inferiority of 0.005% Latanoprost ophthalmic solution and Xalatan in patients with glaucoma or ocular hypertension. J Glaucoma 22(9):707–712CrossRef
11.
Hashemi M, Miraftabi A, Nilforoushan N, Ghasemi Falaranjani K, Pakdel F, Soudi R et al (2012) Comparison of the efficacy and tolerability of Xalatan and Xalabiost (Generic Latanoprost) in adults with open angle glaucoma and ocular hypertension. A two-center, randomized crossover trial. Iran J Ophthalmol 24(3):11–18
12.
Narayanaswamy A, Neog A, Baskaran M, Gewge R, Lingham V, Desai C, Rajadhyaksha V (2007) A randomized crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with gerneric Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian J Ophthalmol 55(2):127–131CrossRef
13.
Scherer WJ (2004) A retrospective review of non-responders to Latanoprost. J Ocular Pharmacol Ther 18(3):287–291CrossRef
14.
Ikeda Y, Mori K, Ishibashi T, Naruse S, Nakajima N, Kinoshita S (2006) Latanoprost nonresponders with open-angle glaucoma in the Japanese population. Jap J Ophthalmol 50(2):153–157CrossRef
15.
Rossetti L, Gandolfi S, Traverso C, Montanari P, Uva M, Manni G et al (2006) An evaluation of the rate of non-responders to Latanoprost therapy. J Glaucoma 15(3):238–243CrossRef
16.
Stein JD, Shekhawat N, Talwar N, Balkrishnan R (2015) Importance of the introduction of generic Latanoprost on glaucoma medication adherence. Ophthalmol 122(4):738747CrossRef
Metadata
Title
Efficacy of locally produced Latanoprost in the control of intraocular pressure in patients with primary open-angle glaucoma
Authors
Pir Salim Mahar
Nadeem H. Butt
Syed Imtiaz Ali
Publication date
01-12-2018
Publisher
Springer Netherlands
Published in
International Ophthalmology / Issue 6/2018
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-017-0773-2

Other articles of this Issue 6/2018

International Ophthalmology 6/2018 Go to the issue

Original Paper

Assessment of ocular toxoplasmosis patients reported at a tertiary center in the northeast of Iran

Original Paper

Scleral fixated intraocular lens implantation with a modified Z-suture technique

Original Paper

VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema

Case Report

Triple chamber: a clinical rarity after deep anterior lamellar keratoplasty and role of optical coherence tomography in management

Original Paper

The efficacy of latent tuberculosis treatment for immunocompetent uveitis patients with a positive T-SPOT.TB test: 6-year experience in a tuberculosis endemic region

Correction

Correction to: Assessment of ocular toxoplasmosis patients reported at a tertiary center in the northeast of Iran